The global incidence of multiple myeloma is on the rise, particularly among men, people 50 years of age or older, and those from high-income countries.
Final results from the GRIFFIN trial support adding daratumumab to induction, consolidation, and maintenance therapy for patients with newly diagnosed, transplant-eligible multiple myeloma.